Vousden Karen H 4

What Happened

• Karen H. Vousden, a non-employee director of Bristol Myers Squibb Co. (BMY), was granted 3,996.367 Deferred Share Units on Feb 1, 2026. The units are valued at $55.05 each for a total grant value of $220,000. The transaction is reported as an award/acquisition (derivative), not an open-market purchase.

Key Details

• Transaction date and price: Feb 1, 2026; 3,996.367 units at $55.05 per share (total $220,000).
• Security type: Deferred Share Units (derivative award) under the company’s non-employee director deferred compensation plan.
• Settlement: Per footnote, each Deferred Share Unit will convert into one share of common stock upon settlement — typically when the director leaves the board or at a later date the director specified.
• Additional note: Footnote also indicates this includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
• Shares owned after transaction: Not specified in the provided filing.
• Timeliness: Reported Feb 3, 2026 for a Feb 1, 2026 transaction (filed within the typical two-business-day Form 4 reporting window).

Context

• These awards are a form of deferred compensation for non-employee directors and are not an immediate cash purchase or sale of shares. They become actual shares only upon settlement per the plan terms. Such grants are routine for director compensation and do not, by themselves, indicate the director’s near-term trading intent.